Abstract: To study Astragaloside Ⅳ(AS -Ⅳ) in normal mice (db/m) and type 2 diabetic nephropathy (db/db) mice in vivo tissue distribution difference,the purpose of this study was to provide experimental basis for the clinical application of AS-Ⅳagainst type 2 diabetic nephropathy and new drugs research and development. Normal mice (db/m) and type 2 diabetic nephropathy (db/db) mice were injected intravenously with AS-Ⅳ 8 mg/kg dose,the mice were killed at 15 min,2 h and 4 h,to collect heart,liver,spleen,lung,kidney,stomach,intestine,brain,muscle tissues.The content of AS-Ⅳ in each tissues were determined by HPLC-MS/MS,and the distribution of AS-Ⅳ in each tissues under normal and pathological conditions was compared.In type 2 diabetic nephropathy,the concentrations of AS-Ⅳ in liver,spleen,lung and kidney were 349.72±70.72,370.69±45.46,583.65±581.75,4290.63±485.34 ng/mL.In the normal state,the concentrations of AS-IV in liver,spleen,lung and kidney were 202.47±47.96,267.92±41.24,472.80±867.51,234.55±256.11 ng/mL,respectively.The concentration of AS-Ⅳ in liver,spleen,lung and kidney was significantly higher than that in normal tissues(P<0.05).After intravenous injection,lung,kidney,heart,stomach and spleen were the main distribution organs,and the concentration was the highest in lung and kidney.Under the pathological condition,the tissue distribution of AS-Ⅳ changed to a certain extent,which provided an experimental basis for the clinical rational application and development of AS-Ⅳ in the prevention and treatment of type 2 diabetic nephropathy.

Key words: Astragaloside Ⅳ, type 2 diabetic nephropathy, HPLC-MS/MS, tissue distribution